Keros Therapeutics (KROS) Cash & Current Investments: 2019-2025
Historic Cash & Current Investments for Keros Therapeutics (KROS) over the last 7 years, with Sep 2025 value amounting to $693.5 million.
- Keros Therapeutics' Cash & Current Investments rose 30.68% to $693.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 billion, marking a year-over-year increase of 55.79%. This contributed to the annual value of $559.9 million for FY2024, which is 69.09% up from last year.
- According to the latest figures from Q3 2025, Keros Therapeutics' Cash & Current Investments is $693.5 million, which was up 0.47% from $690.2 million recorded in Q2 2025.
- In the past 5 years, Keros Therapeutics' Cash & Current Investments registered a high of $720.5 million during Q1 2025, and its lowest value of $215.6 million during Q2 2022.
- For the 3-year period, Keros Therapeutics' Cash & Current Investments averaged around $485.1 million, with its median value being $442.4 million (2024).
- Examining YoY changes over the last 5 years, Keros Therapeutics' Cash & Current Investments showed a top increase of 368.11% in 2021 and a maximum decrease of 13.48% in 2021.
- Over the past 5 years, Keros Therapeutics' Cash & Current Investments (Quarterly) stood at $230.0 million in 2021, then increased by 21.30% to $279.0 million in 2022, then rose by 18.67% to $331.1 million in 2023, then surged by 69.09% to $559.9 million in 2024, then soared by 30.68% to $693.5 million in 2025.
- Its Cash & Current Investments was $693.5 million in Q3 2025, compared to $690.2 million in Q2 2025 and $720.5 million in Q1 2025.